Compare Stocks: RNTX, GALT, STRO, and BCYC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCYC Bicycle Therapeutics	$3.38 -5.1%	$3.96	$3.33 ▼ $9.16	$236.58M	1.68	437,341 shs	728,668 shs
GALT Galectin Therapeutics	$3.90 +3.7%	$3.74	$2.03 ▼ $7.13	$256.84M	0.38	294,776 shs	220,095 shs
RNTX Rein Therapeutics	$0.80 -6.0%	$0.79	$0.69 ▼ $2.18	$69.07M	1.35	383,509 shs	477,517 shs
STRO Sutro Biopharma	$15.35 -3.9%	$20.13	$7.15 ▼ $43.85	$254.52M	1.49	322,945 shs	361,334 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCYC Bicycle Therapeutics	0.00%	-8.15%	-20.28%	-22.30%	-59.42%
GALT Galectin Therapeutics	0.00%	0.00%	-10.34%	-13.53%	-6.70%
RNTX Rein Therapeutics	0.00%	+6.99%	-5.09%	-19.24%	-32.14%
STRO Sutro Biopharma	0.00%	-3.94%	-25.27%	-49.56%	+69.99%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCYC Bicycle Therapeutics	$3.38 -5.1%	$3.96	$3.33 ▼ $9.16	$236.58M	1.68	437,341 shs	728,668 shs
GALT Galectin Therapeutics	$3.90 +3.7%	$3.74	$2.03 ▼ $7.13	$256.84M	0.38	294,776 shs	220,095 shs
RNTX Rein Therapeutics	$0.80 -6.0%	$0.79	$0.69 ▼ $2.18	$69.07M	1.35	383,509 shs	477,517 shs
STRO Sutro Biopharma	$15.35 -3.9%	$20.13	$7.15 ▼ $43.85	$254.52M	1.49	322,945 shs	361,334 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCYC Bicycle Therapeutics	0.00%	-8.15%	-20.28%	-22.30%	-59.42%
GALT Galectin Therapeutics	0.00%	0.00%	-10.34%	-13.53%	-6.70%
RNTX Rein Therapeutics	0.00%	+6.99%	-5.09%	-19.24%	-32.14%
STRO Sutro Biopharma	0.00%	-3.94%	-25.27%	-49.56%	+69.99%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCYC Bicycle Therapeutics	2.44	Hold	$13.86	309.97% Upside
GALT Galectin Therapeutics	2.00	Hold	$11.00	182.05% Upside
RNTX Rein Therapeutics	2.25	Hold	$6.00	649.34% Upside
STRO Sutro Biopharma	3.00	Buy	$49.50	222.48% Upside

Current Analyst Ratings Breakdown

Latest RNTX, GALT, STRO, and BCYC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/30/2026	STRO Sutro Biopharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$49.00
9/16/2026	STRO Sutro Biopharma	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/14/2026	GALT Galectin Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/7/2026	STRO Sutro Biopharma	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/21/2026	RNTX Rein Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/18/2026	RNTX Rein Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/13/2026	STRO Sutro Biopharma	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/13/2026	STRO Sutro Biopharma	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Market Outperform	$41.00 ➝ $34.00
8/13/2026	STRO Sutro Biopharma	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$60.00
8/11/2026	GALT Galectin Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/7/2026	STRO Sutro Biopharma	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$48.00

(Data available from 10/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCYC Bicycle Therapeutics	$72.86M	3.25	N/A	N/A	$8.79 per share	0.38
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	($1.99) per share	N/A
RNTX Rein Therapeutics	N/A	N/A	$0.06 per share	14.00	($1.07) per share	N/A
STRO Sutro Biopharma	$102.48M	2.48	N/A	N/A	($15.43) per share	-0.99

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCYC Bicycle Therapeutics	-$218.96M	-$2.73	N/A	N/A	N/A	-311.11%	-33.22%	-27.79%	10/29/2026 (Estimated)
GALT Galectin Therapeutics	-$30.84M	-$0.43	N/A	N/A	N/A	N/A	N/A	-176.83%	11/13/2026 (Estimated)
RNTX Rein Therapeutics	-$49.87M	-$1.72	N/A	N/A	N/A	N/A	N/A	-63.69%	N/A
STRO Sutro Biopharma	-$191.09M	-$11.97	N/A	N/A	N/A	-395.25%	N/A	-88.12%	11/5/2026 (Estimated)

Latest RNTX, GALT, STRO, and BCYC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/29/2026	Q3 2026	BCYC Bicycle Therapeutics	-$0.3990	N/A	N/A	N/A	$12.22 million	N/A
8/14/2026	Q2 2026	GALT Galectin Therapeutics	-$0.09	-$0.14	-$0.05	-$0.14	N/A	N/A
8/14/2026	Q2 2026	RNTX Rein Therapeutics	-$0.27	-$0.10	+$0.17	-$0.10	N/A	N/A
8/12/2026	Q2 2026	STRO Sutro Biopharma	-$2.19	-$2.33	-$0.14	-$2.33	$11.96 million	$9.84 million
7/30/2026	Q2 2026	BCYC Bicycle Therapeutics	-$0.5756	-$0.72	-$0.1444	-$0.72	$4.22 million	$0.63 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCYC Bicycle Therapeutics	N/A	N/A	N/A	N/A	N/A
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	N/A
RNTX Rein Therapeutics	N/A	N/A	N/A	N/A	N/A
STRO Sutro Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCYC Bicycle Therapeutics	N/A	12.08	12.08
GALT Galectin Therapeutics	N/A	0.10	0.10
RNTX Rein Therapeutics	N/A	4.27	4.27
STRO Sutro Biopharma	N/A	3.32	3.32

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCYC Bicycle Therapeutics	86.15%
GALT Galectin Therapeutics	11.68%
RNTX Rein Therapeutics	90.89%
STRO Sutro Biopharma	96.99%

Insider Ownership

Company	Insider Ownership
BCYC Bicycle Therapeutics	22.00%
GALT Galectin Therapeutics	52.60%
RNTX Rein Therapeutics	1.50%
STRO Sutro Biopharma	1.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCYC Bicycle Therapeutics	288	69.99 million	54.60 million	Optionable
GALT Galectin Therapeutics	9	65.86 million	31.22 million	Optionable
RNTX Rein Therapeutics	10	86.27 million	84.97 million	N/A
STRO Sutro Biopharma	128	16.58 million	16.28 million	Optionable

RNTX, GALT, STRO, and BCYC Headlines

Recent News About These Companies

Sutro Biopharma, Inc. (NASDAQ:STRO) Stock Has Average Price Target of $49.50 According to Brokerages

2 hours ago | americanbankingnews.com

Sutro Biopharma, Inc. (NASDAQ:STRO) Stock Rated "Buy" by Wall Street Brokerages

2 hours ago | marketbeat.com

Wells Fargo & Company Initiates Coverage on Sutro Biopharma (NASDAQ:STRO)

October 2 at 1:42 AM | americanbankingnews.com

Sutro Biopharma (NASDAQ:STRO) Coverage Initiated by Analysts at Wells Fargo & Company

September 30, 2026 | marketbeat.com

Sutro Biopharma, Inc. annonce la nomination de Lucas Donigian au poste de vice-président senior chargé du développement commercial, à compter du 28 septembre 2026

September 30, 2026 | zonebourse.comZ

Sutro Biopharma, Inc. Announces Appointment of Lucas Donigian as Senior Vice President, Business Development, Effective September 28, 2026

September 30, 2026 | marketscreener.comM

Sutro Biopharma nomina Lucas Donigian come responsabile dello sviluppo

September 29, 2026 | it.investing.com

Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development

September 29, 2026 | globenewswire.com

Sutro Biopharma (NASDAQ:STRO) Rating Lowered to "Strong Sell" at Wall Street Zen

September 19, 2026 | marketbeat.com

Sutro Biopharma (NASDAQ:STRO) Raised to Strong-Buy at Mizuho

September 18, 2026 | marketbeat.com

Sutro Biopharma (NASDAQ:STRO) Rating Increased to Strong-Buy at Mizuho

September 9, 2026 | marketbeat.com

Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Consensus Rating of "Buy" from Brokerages

September 9, 2026 | marketbeat.com

Seven Fleet Capital Management LP Makes New Investment in Sutro Biopharma, Inc. $STRO

September 5, 2026 | marketbeat.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sutro Biopharma (STRO), Summit Therapeutics (SMMT) and Altimmune (ALT)

August 14, 2026 | theglobeandmail.com

STRO stock plummets 15% — what drove the selloff?

August 12, 2026 | msn.com

Why is Sutro Biopharma Stock Falling On Wednesday?

August 12, 2026 | benzinga.com

Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study

August 12, 2026 | globenewswire.com

News Flash: Analysts Just Made A Massive Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) Forecasts

May 28, 2026 | finance.yahoo.com

US$47.10 - That's What Analysts Think Sutro Biopharma, Inc. (NASDAQ:STRO) Is Worth After These Results

May 17, 2026 | finance.yahoo.com

Wedbush upgrades Sutro Biopharma (STRO)

May 16, 2026 | msn.com

Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights

May 14, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RNTX, GALT, STRO, and BCYC Company Descriptions

Bicycle Therapeutics NASDAQ:BCYC

$3.38 -0.18 (-5.06%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$3.38 0.00 (0.00%)

As of 10/2/2026 07:30 PM Eastern

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Galectin Therapeutics NASDAQ:GALT

$3.90 +0.14 (+3.72%)

As of 10/2/2026 04:00 PM Eastern

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Rein Therapeutics NASDAQ:RNTX

$0.80 -0.05 (-6.03%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$0.79 -0.01 (-1.46%)

As of 10/2/2026 07:30 PM Eastern

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

Sutro Biopharma NASDAQ:STRO

$15.35 -0.62 (-3.88%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$15.36 +0.01 (+0.03%)

As of 10/2/2026 07:33 PM Eastern

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RNTX, GALT, STRO, and BCYC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RNTX, GALT, STRO, and BCYC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RNTX, GALT, STRO, and BCYC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RNTX, GALT, STRO, and BCYC Company Descriptions

Bicycle Therapeutics NASDAQ:BCYC

Galectin Therapeutics NASDAQ:GALT

Rein Therapeutics NASDAQ:RNTX

Sutro Biopharma NASDAQ:STRO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RNTX, GALT, STRO, and BCYC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RNTX, GALT, STRO, and BCYC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RNTX, GALT, STRO, and BCYC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RNTX, GALT, STRO, and BCYC Company Descriptions

Bicycle Therapeutics NASDAQ:BCYC

Galectin Therapeutics NASDAQ:GALT

Rein Therapeutics NASDAQ:RNTX

Sutro Biopharma NASDAQ:STRO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools